Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283202 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03283202 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 35 participants.
The verdict
NCT03283202, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell Lymphoma (DLBCL) that has poor risk factors. Approximately 40% of patients diagnosed with DLBCL are not cured with R-CHOP alone and would need additional treatment for DLBCL in the future. The addition of the experimental drug avadomide (CC-122) with R-CHOP could help in controlling DLBCL in this patient population.
Interventions
- DRUG Rituximab
- DRUG Vincristine
- DRUG Prednisone
- DRUG Avadomide (CC-122)
- DRUG Cyclophosphamide 750mg/m2 by IV infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2020-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283202
The ClinicalTrials.gov registry entry for NCT03283202 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT03283202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283202 about?
NCT03283202 is a clinical study titled "Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors". This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell Lymphoma (DLBCL) that has poor risk factors. Approximately 40% of patie...
What is the current status of trial NCT03283202?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-10-04. Estimated completion is 2020-12-16.
What interventions are being tested in trial NCT03283202?
The interventions under investigation include: Rituximab (DRUG), Vincristine (DRUG), Prednisone (DRUG), Avadomide (CC-122) (DRUG), Cyclophosphamide 750mg/m2 by IV infusion (DRUG).
Who is sponsoring clinical trial NCT03283202?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.